160 related articles for article (PubMed ID: 28911001)
1. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
[TBL] [Abstract][Full Text] [Related]
2. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
van Hest LP; Ruijs MW; Wagner A; van der Meer CA; Verhoef S; van't Veer LJ; Meijers-Heijboer H
Fam Cancer; 2007; 6(3):311-6. PubMed ID: 17318340
[TBL] [Abstract][Full Text] [Related]
3. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
4. Germline TP53 mutational spectrum in French Canadians with breast cancer.
Arcand SL; Akbari MR; Mes-Masson AM; Provencher D; Foulkes WD; Narod SA; Tonin PN
BMC Med Genet; 2015 Apr; 16():24. PubMed ID: 25925845
[TBL] [Abstract][Full Text] [Related]
5. Inherited
Guha T; Malkin D
Cold Spring Harb Perspect Med; 2017 Apr; 7(4):. PubMed ID: 28270529
[TBL] [Abstract][Full Text] [Related]
6. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022).
Sánchez-Heras AB; Ramon Y Cajal T; Pineda M; Aguirre E; Graña B; Chirivella I; Balmaña J; Brunet J;
Clin Transl Oncol; 2023 Sep; 25(9):2627-2633. PubMed ID: 37133731
[TBL] [Abstract][Full Text] [Related]
7. TP53, MSH4, and LATS1 germline mutations in a family with clustering of nervous system tumors.
Kim YH; Ohta T; Oh JE; Le Calvez-Kelm F; McKay J; Voegele C; Durand G; Mittelbronn M; Kleihues P; Paulus W; Ohgaki H
Am J Pathol; 2014 Sep; 184(9):2374-81. PubMed ID: 25041856
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of the possibility of Li-Fraumeni syndrome in cancer patients in East Azarbaijan Province of Iran.
Esmaeilzadeh Aghjeh M; Hosseinpour Feizi MA; Safaralizadeh R; Hosseinpour Feizi AA; Pouladi N
Nucleosides Nucleotides Nucleic Acids; 2024; 43(5):417-426. PubMed ID: 37801337
[TBL] [Abstract][Full Text] [Related]
9. Spectrum and Excess Risk of Gastrointestinal Tumors in Li-Fraumeni Syndrome.
Hatton JN; de Andrade KC; Frone MN; Savage SA; Khincha PP
Clin Gastroenterol Hepatol; 2024 Mar; 22(3):662-665.e1. PubMed ID: 37714395
[TBL] [Abstract][Full Text] [Related]
10. Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review.
Irshaid L; Clark M; Fadare O; Finberg KE; Parkash V
Int J Gynecol Pathol; 2022 May; 41(3):258-267. PubMed ID: 33990091
[TBL] [Abstract][Full Text] [Related]
11. Cancer Risks Associated With
Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
[TBL] [Abstract][Full Text] [Related]
12. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors.
Varley JM; McGown G; Thorncroft M; James LA; Margison GP; Forster G; Evans DG; Harris M; Kelsey AM; Birch JM
Am J Hum Genet; 1999 Oct; 65(4):995-1006. PubMed ID: 10486318
[TBL] [Abstract][Full Text] [Related]
13. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
Kwong A; Shin VY; Ho CYS; Au CH; Slavin TP; Weitzel JN; Chan TL; Ma ESK
BMC Cancer; 2020 Nov; 20(1):1053. PubMed ID: 33138793
[TBL] [Abstract][Full Text] [Related]
14. Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models.
Chan CS; Sun Y; Ke H; Zhao Y; Belete M; Zhang C; Feng Z; Levine AJ; Hu W
Life Sci Alliance; 2021 Mar; 4(3):. PubMed ID: 33376133
[No Abstract] [Full Text] [Related]
15. Genetic modifiers of p53: opportunities for breast cancer therapies.
Majhi PD; Sharma A; Jerry DJ
Oncotarget; 2023 Mar; 14():236-241. PubMed ID: 36961913
[No Abstract] [Full Text] [Related]
16. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features of Li-Fraumeni Syndrome in Korea.
Song R; Kong SY; Choi W; Lee EG; Woo J; Han JH; Lee S; Kang HS; Jung SY
Cancer Res Treat; 2024 Jan; 56(1):334-341. PubMed ID: 37562436
[TBL] [Abstract][Full Text] [Related]
18. Sotos Syndrome with NSDI Gene Mutations and Li-Fraumeni Syndrome with TP53 Gene Mutations in a Patient with Multiple Gastric Signet-Ring Cell Carcinomas.
Li Y; Wang W; Sun W; Wu X; Zhao B; Dou X; Wang L; Chen M
Dig Dis Sci; 2024 Feb; 69(2):315-317. PubMed ID: 38147236
[No Abstract] [Full Text] [Related]
19. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.
Herbert BS; Chanoux RA; Liu Y; Baenziger PH; Goswami CP; McClintick JN; Edenberg HJ; Pennington RE; Lipkin SM; Kopelovich L
Oncotarget; 2010 Oct; 1(6):405-422. PubMed ID: 21311097
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of the prevalence of autoimmune disorders in Li-Fraumeni syndrome.
Obregón IH; de Andrade KC; Bremer RC; Khincha PP; Savage SA
Fam Cancer; 2023 Jul; 22(3):319-321. PubMed ID: 36627407
[No Abstract] [Full Text] [Related]
[Next] [New Search]
